Converting an injectable protein therapeutic into an oral form: Phenylalanine ammonia lyase for phenylketonuria

Molecular Genetics and Metabolism

Volumn 99, Issue 1, 2010, Pages 4-9

  Kang, Tse Siang ^a,c   Wang, Lin ^a   Sarkissian, Christineh N ^b   Gámez, Alejandra ^a,d   Scriver, Charles R ^b   Stevens, Raymond C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

Enzyme substitution therapy; Metabolic disorder; Phenylketonuria; Therapeutic development

Indexed keywords

CHYMOTRYPSIN; LYSINE; PHENYLALANINE AMMONIA LYASE; PROTEINASE; SILICON DIOXIDE; TRYPSIN;

ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; PH; PHENYLKETONURIA; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

ADMINISTRATION, ORAL; ANABAENA VARIABILIS; BACTERIAL PROTEINS; BINDING SITES; CHYMOTRYPSIN; ENZYME REPLACEMENT THERAPY; ENZYME STABILITY; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PHENYLALANINE AMMONIA-LYASE; PHENYLKETONURIAS; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; SILICON DIOXIDE; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL; TRYPSIN;

EID: 71949122812     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.09.002     Document Type: Article

References (20)

1. K. Donlon, H. Levy, C.R. Scriver, Hyperphenylalaninemia: phenylalanine hydroxylase deficiency, in: The metabolic and molecular bases of inherited disease, McGraw-Hill/Medical Publishing Division, New York, 2007 (Chapter 77). Available from: .
2. Gamez A., Wang L., Straub M., Patch M.G., and Stevens R.C. Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase. Molecular Therapy 9 (2004) 124-129
3. Sarkissian C.N., et al. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 2339-2344
4. Bourget L., and Chang T.M. Artificial cell-microencapsulated phenylalanine ammonia-lyase. Applied Biochemistry and Biotechnology 10 (1984) 57-59
5. Sarkissian C.N., and Gamez A. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?. Molecular Genetics and Metabolism 86 Suppl. 1 (2005) S22-S26
6. Hoskins J.A., and Gray J. Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans. Research Communications in Chemical Pathology and Pharmacology 35 (1982) 275-282
7. Ambrus C.M., et al. Phenylalanine depletion for the management of phenylketonuria: use of enzyme reactors with immobilized enzymes. Science (New York, NY) 201 (1978) 837-839
8. Wang L., et al. Structural and biochemical characterization of the therapeutic Anabaena variabilis phenylalanine ammonia lyase. Journal of Molecular Biology 380 (2008) 623-635
9. Sarkissian C.N., et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proceedings of the National Academy of Sciences of the United States of America 105 (2008) 20894-20899
10. Shah R.M., and D'Mello A.P. Strategies to maximize the encapsulation efficiency of phenylalanine ammonia lyase in microcapsules. International Journal of Pharmaceutics 356 (2008) 61-68
11. Frenkel-Mullerad H., and Avnir D. Sol-gel materials as efficient enzyme protectors: preserving the activity of phosphatases under extreme ph conditions. Journal of the American Chemical Society 127 (2005) 8077-8081
12. Bhatia R.B., Brinker C.J., Gupta A.K., and Singh A.K. Aqueous sol-gel process for protein encapsulation. Chemistry of Materials 12 (2000) 2434-2441
13. Ellerby L.M., et al. Encapsulation of proteins in transparent porous silicate glasses prepared by the sol-gel method. Science (New York, NY) 255 (1992) 1113-1115
14. Barbe C., et al. Silica particles: a novel drug-delivery system. Advanced Material 16 (2004) 1959-1965
15. Lebert J.M., Forsberg E.M., and Brennan J.D. Solid-phase assays for small molecule screening using sol-gel entrapped proteins. Biochemistry and Cell Biology 86 (2008) 100-110
16. Delgado C., Francis G.E., and Fisher D. The uses and properties of PEG-linked proteins. Critical Reviews in Therapeutic Drug Carrier Systems 9 (1992) 249-304
17. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nature Reviews 2 (2003) 214-221
18. Leader B., Baca Q.J., and Golan D.E. Protein therapeutics: a summary and pharmacological classification. Nature Reviews 7 (2008) 21-39
19. Rigby S.P., Fairhead M., and van der Walle C.F. Engineering silica particles as oral drug delivery vehicles. Current Pharmaceutical Design 14 (2008) 1821-1831
20. Moffitt M.C., Louie G.V., Bowman M.E., Pence J., Noel J.P., and Moore B.S. Discovery of two cyanobacterial phenylalanine ammonia lyases: kinetic and structural characterization. Biochemistry 46 (2007) 1004-1012